LncRNA CALML3-AS1 modulated by m 6 A modification induces BTNL9 methylation to drive non-small-cell lung cancer progression
Heng Zhang,Shao-Qiang Wang,Jie-Bo Zhu,Li-Na Wang,Hang Lin,Lin-Feng Li,Yuan-Da Cheng,Chao-Jun Duan,Chun-Fang Zhang
DOI: https://doi.org/10.1038/s41417-023-00670-7
IF: 5.854
2023-10-28
Cancer Gene Therapy
Abstract:Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The carcinogenic roles of lncRNA CALML3 antisense RNA 1 (CALML3-AS1) have been documented. However, the function and potential mechanisms of CALML3-AS1 in the progression of NSCLC need to be further explored. The molecule expression was assessed by qRT-PCR and Western blot. The subcellular localization of CALML3-AS1 was observed by fluorescence in situ hybridization (FISH). The malignant behaviors of NSCLC cells were evaluated by CCK-8, colony formation, EdU, wound healing and transwell assays. In vivo xenograft tumor and liver metastatic models were established. The molecular mechanisms were investigated by RIP, RNA pull-down and ChIP assays. The methylation level was detected by MSP. Herein, we found that CALML3-AS1 was upregulated, while butyrophilin-like 9 (BTNL9) was downregulated in NSCLC. Functionally, CALML3-AS1 depletion repressed NSCLC cell malignant phenotypes, in vivo tumor growth, and liver metastasis. Mechanistically, AlkB homolog 5 (ALKBH5) enhanced CALML3-AS1 stability via N 6 -methyladenosine (m 6 A) demethylation, whereas m 6 A reader YTH domain-containing 2 (YTHDC2) destabilized CALML3-AS1. Moreover, CALML3-AS1 inhibited BTNL9 transcription and expression through the recruitment of Zeste homolog 2 (EZH2). Rescue experiments demonstrated that BTNL9 downregulation counteracted sh-CALML3-AS1-mediated antitumor effects on NSCLC. Taken together, CALML3-AS1 modulated by ALKBH5 and YTHDC2 in an m 6 A modification dependent manner drives NSCLC progression via epigenetically repressing BTNL9.
oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology